Editorial team
ioQuanta Research Desk
-
Evidence date ·Approved BCMA-targeting CAR T therapies can delay myeloma progression, but relapse remains possible
Review or Meta-AnalysisIn separate randomized trials, two BCMA CAR T therapies delayed myeloma progression and improved responses versus standard care. Relapse and serious side effects remain.
-
Evidence date ·Why are researchers looking beyond one immune pathway in head and neck cancer?
Review or Meta-AnalysisA 2025 review surveys four immune targets beyond PD-1/PD-L1 in head and neck cancer. It does not establish patient benefit or the safety of combinations.
-
Evidence date ·How do treatment choices vary in high-risk penile cancer care?
Peer-Reviewed PaperA survey of 39 European specialists found varied treatment preferences and limited integration of tumor sequencing. It cannot show which approach works best.
-
Evidence date ·Could treating senescent ovarian cells protect ovarian function?
Review or Meta-AnalysisA review surveys mouse studies of ovarian aging and a metformin trial for chemotherapy damage. None shows that treatment preserves fertility in women as they age.
-
Evidence date ·Why researchers are engineering a different immune cell for solid tumors
Review or Meta-AnalysisThe January 2025 review explains how CAR-iNKT cells pair native lipid recognition with an added tumor-targeting receptor. Patient benefit remains unproven.
-
Evidence date ·How researchers are exploring different routes to tailored cancer treatment
Review or Meta-AnalysisA review surveys molecular, immune and gene-expression approaches to cancer therapy. It does not show whether matching a treatment to a patient improves outcomes.
-
Evidence date ·How drug carriers and immune treatments might address hard-to-treat digestive cancers
Review or Meta-AnalysisA 2025 review describes drug carriers and immune treatments being explored for digestive cancers. Their value for patients depends on clinical effectiveness and toxicity.
-
Evidence date ·Could changing aging processes protect health and independence?
Review or Meta-AnalysisA 2025 review examines aging pathways, animal findings and limited human evidence. Whether targeting those pathways preserves health or independence remains unproven.
-
Evidence date ·Could toxic RNA make cells age early in myotonic dystrophy?
Review or Meta-AnalysisA 2024 review examines signs of senescence in myotonic dystrophy and summarizes drug tests in cells and flies. Benefits for people remain unproven.
-
Evidence date ·How aging changes the body’s barriers and immune response to infection
Review or Meta-AnalysisThe review traces immune aging from cellular maintenance to airway defenses and explains why risk varies. Proposed treatments still need testing in older adults.